key: cord-0857858-rx643565 authors: nan title: Vaccination Against SARS-CoV-2 in Immunosuppressed Patients with Rheumatic Diseases: Position Statement of the Greek Rheumatology Society date: 2020-12-28 journal: Mediterr J Rheumatol DOI: 10.31138/mjr.31.4.430 sha: c9bdb6ef5a2380cc162c162f9d98fe3b2f073f3d doc_id: 857858 cord_uid: rx643565 nan Patients with autoimmune inflammatory rheumatic diseases are at higher risk for serious complications of bacterial or viral infections that can be prevented by appropriate vaccination. [1] [2] [3] The European League Against Rheumatism (EULAR) 2 and the Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE) 4 have published their recommendations regarding vaccination in this population. Considering the upcoming vaccination of the population worldwide against SARS-CoV-2, the Greek Rheumatology Society presents the available data and Recommendations from international [5] [6] [7] [8] [9] and local 10 Health Authorities as well as its Position regarding the vaccination of immunosuppressed rheumatic patients. To date (December 2020), 5 [10] [11] [12] Such vaccines are highly immunogenic in humans eliciting strong B cell (production of protective antibodies) and T cell responses, 11, [13] [14] [15] [16] although the duration of their protection remains to be determined. Since these vaccines do not contain the live virus, there is no danger for viral transmission after vaccination, while mRNA is destroyed after a few days by the host. 11 Available data from human randomised controlled trials (RCTs) to date for these two mRNA vaccines show that their efficacy for preventing symptomatic COVID-19 infection ranges from 94% 16 to 95%, 11, 17 while their respective efficacy in preventing severe COVID-19 infection ranges from 89% 11,18 to 100%. 17 Regarding safety, the short-term safety data available, show that vaccinated persons experience mostly local (pain, erythema) or mild systemic reactions (fatigue, headache, fever, arthralgias). 6 Severe anaphylactic reactions have not been observed in the clinical trials of both vaccines, but there have been rare cases of anaphylaxis in persons vaccinated outside of clinical trials as with any other vaccine. These vaccines will be administered worldwide in COVID-19 vaccination centres under direct medical supervision and observation. 6 According to their emergency authorisation use prescribing information, these vaccines are only contra-indicated in individuals with a known history of severe allergic reaction (eg, anaphylaxis) to any of their components. 6, 19, 20 Patients with such history should discuss it prior to their vaccination with the health personnel of the COVID-19 vaccination centres. Data regarding the safety and efficacy of these vaccines in immunocompromised patients is at present limited. Although, in the clinical studies that led to the approval of these vaccines immunocompromised patients were excluded, 12, 17 in one of the 2 RCTs, patients with history of malignancy (n=1.395), AIDS/HIV (n=121) or rheumatic disease (n=118) were included. 12 There was no difference in the vaccine efficacy or safety in these patients compared to the rest of the vaccinated patients. Nevertheless, patients with rheumatic conditions who are immunocompromised due to their immunosuppressive therapy or due to their disease may have a decreased response to these new vaccines as with other vaccines currently in clinical use. 2,3 Health authorities in the UK, 7 US, 5-6 and other countries including Greece 10 recommend that all immunosuppressed patients should be vaccinated against SARS-CoV-2. In general, in these early phases of the vaccination process where the availability of the vaccines may be limited, priority for vaccination has been given to critical infrastructure workers (such as frontline health care personnel, staff working in nursing homes, etc.) and high-risk patients for severe COVID-19 (including elderly people, residents of nursing homes and assisted living facilities, as well as patients with underlying medical conditions, which put them at higher risk for severe disease or death). [5] [6] [7] Patients who are immunosuppressed due to their disease or immunosuppressive therapies are generally included in the prioritized high-risk population for vaccination against SARS-CoV-2. [5] [6] [7] POSITION STATEMENT Based on the long-term experience with vaccinations in patients with rheumatic diseases, 1-3 the available data from clinical trials, 12, 17 and the most recent recommendations from Health Authorities, 5-7,10 the Greek Rheumatology Society (ERE-EPERE) recommends that all immunosuppressed patients with rheumatic conditions should be vaccinated against SARS-CoV-2. The prioritisation of immunosuppressed patients for vaccination will be determined by the Health Authorities. We also recommend that patients should always contact their rheumatologist with any questions that may have prior to their vaccination. Vaccinated patients should continue following existing guidelines regarding protective measures for themselves and people around them (wearing masks, keeping distance from others, avoiding crowds, etc.). This statement will be updated as more data regarding the safety and efficacy of these and other vaccines become available. 2020 432 MEDITERRANEAN JOURNAL OF RHEUMATOLOGY 31 4 2020 Immunogenicity And Safety Of Vaccination In Adult Patients With Autoimmune Inflammatory Rheumatic Diseases: A Systematic Literature Review For The Update Of EULAR Recommendations For Vaccination In Adult Patients With Autoimmune Inflammatory Rheumatic Diseases Immunization In Patients With Inflammatory Rheumatic Diseases Greek Rheumatology Society And Professional Association Of Rheumatologists. Guidelines For The Vaccination Of Rheumatic Patients On Immunomodulatory Therapies Vaccination Program Interim Playbook For Jurisdiction Operations html?cdc_aa_refval=https%3a%2f%2fwww.cdc.gov%2fvac-cines%2fcovid-19%2finfo-by-product%2fpfizer%2fclinical-considerations Advise On Priority Groups For COVID-19 Vaccination (UK). Accessed At Update: Information From The American College Of Rheumatology Regarding Vaccination Against SARS-Cov-2 National Immunization Committee. Educational Manual For COVID-19 Vaccination Centers. Version 1.0 Mrna Vaccines -A New Era In Vaccinology Safety And Efficacy Of The BNT162b2 Mrna Covid-19 SARS-Cov-2 Mrna Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated With Neutralizing Antibody Generation Mrna-1273 Vaccination An Mrna Vaccine Against SARS-Cov-2 -Preliminary Report Safety And Immunogenicity Of SARS-CoV-2 mRNA-1273 Vaccine In Older Adults FDA Briefing Document, Moderna COVID-19 Vaccine FDA Briefing Document, Pfizer-Biontech COVID-19 Vaccine Pfizer-Biontech COVID-19 Vaccine EUA Fact Sheet For HCP Fact-Sheet-Providers-Moderna COVID-19 Vaccine The authors declare no conflict of interest.